Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomised, Placebo-Controlled, Ascending Single and Multiple Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of PAT-1251 in Healthy Adult Subjects

Next Previous
X
Search
Trial Profile

A Phase 1, Randomised, Placebo-Controlled, Ascending Single and Multiple Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of PAT-1251 in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GB 2064 (Primary)
  • Indications Hepatic fibrosis; Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Sponsors PharmAkea Therapeutics

    • Most Recent Events

    • 22 Aug 2017 According to a PharmAkea Therapeutics media release, the data from this study will inform the dose selection and study design for a subsequent Phase 2 proof-of-concept study in Idiopathic-pulmonary-fibrosis.
    • 22 Aug 2017 Results published in a PharmAkea Therapeutics media release.
    • 28 Nov 2016 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top